A Phase 2b Randomized, Double-blind, Placebo Controlled, Multi-center 12-week Study With an Additional 40-week Follow-up Assessment of Efficacy, Safety and Tolerability of M1095 in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2018
At a glance
- Drugs ALX 0761 (Primary) ; Secukinumab
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Avillion
- 19 Sep 2018 Status changed from not yet recruiting to recruiting.
- 16 Feb 2018 According to an Avillion media release, company has received the FDA acceptance for the IND application for this study.
- 20 Dec 2017 Status changed from planning to not yet recruiting.